Clinical Evidence Dashboard

Real Data. Real Results.

Every treatment we prescribe is backed by peer-reviewed clinical trials and NICE guidance. Explore the evidence across all 6 condition areas — 65 treatments, 35 conditions.

Dashboard last refreshed13 Nov 2026 · 14:02
NICE TA875

Medically Supervised Weight Management

Obesity is a complex, chronic disease — not a lifestyle choice. It is driven by powerful hormonal, genetic and neurological signals that override willpower. GLP-1 receptor agonists (such as semaglutide and tirzepatide) work with your biology, not against it, by modulating the hormones that control hunger, satiety and blood glucose.

Start Consultation →
Evidence data auto-synced from live treatment catalogue·Last reviewed by GPhC-registered Pharmacist Prescriber13 November 2026

Weight loss (obesity)· 6 treatments

Avg % Body Weight Lost (72 weeks)

0%50%100%PlaceboSaxendaOrlistatFoundayoWegovy PillWegovyMounjaro

Weight loss over time (Weeks)

012243652720%6%12%18%24%
91%

Patients ≥5% loss

Mounjaro® (Tirzepatide)

Dual GIP/GLP-1 Receptor Agonist · Injectable — once weekly

22.5% mean body weight reduction at 72 weeks (SURMOUNT-1). 64% achieved ≥15% weight loss at highest dose.

SURMOUNT-1 (NEJM 2022); NICE TA875 (2023) · NICE TA875 (2023) · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · SPS Tirzepatide guidance · MHRA Drug Safety Update (GLP-1 RAs)

Reviewed by pharmacist: 13 November 2026

Wegovy® (Semaglutide 2.4mg)

GLP-1 Receptor Agonist · Injectable — once weekly

20.7% mean weight reduction at 72 weeks (STEP 1). 86% of participants lost ≥5% body weight.

STEP 1 (NEJM 2021); NICE TA875 (2023) · NICE TA875 (2023) · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · SPS Semaglutide (Wegovy®) guidance · MHRA Drug Safety Update (GLP-1 RAs)

Reviewed by pharmacist: 13 November 2026

Wegovy® Pill (Oral Semaglutide 25mg)

GLP-1 Receptor Agonist — Oral Formulation · Oral tablet — once daily

13.6% mean body weight reduction at 64 weeks (OASIS-4). 76% achieved ≥5% weight loss vs 31% on placebo. First oral GLP-1 approved for chronic weight management.

OASIS-4 (NEJM 2025); SELECT cardiovascular outcomes trial; first oral GLP-1 for weight loss · NICE TA1085 (2025, oral semaglutide) · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · SPS Oral semaglutide guidance · MHRA Drug Safety Update (GLP-1 RAs)

Reviewed by pharmacist: 13 November 2026

Saxenda® (Liraglutide)

GLP-1 Receptor Agonist · Injectable — once daily

Average 8% body weight loss at 56 weeks (SCALE trial) alongside diet and exercise. Maintenance of weight loss in most patients at 1 year on the 3mg dose.

SCALE (NEJM 2015); NICE TA661 (2022) · NICE TA661 (2022, liraglutide 3mg) · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · SPS Liraglutide guidance · MHRA Drug Safety Update (GLP-1 RAs)

Reviewed by pharmacist: 13 November 2026

Orlistat 120mg (Xenical® / Generic)

Pancreatic Lipase Inhibitor · Oral capsule — 3× daily with meals

Average 5.8kg additional weight loss vs placebo at 1 year. Reduces cardiovascular risk factors and delays onset of Type 2 Diabetes.

NICE CG189 (2014 updated 2023); XENDOS trial · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · NICE CG189 (2014, updated 2023) · BNF Orlistat · SPS Orlistat interactions guidance

Reviewed by pharmacist: 13 November 2026

Foundayo™ (Orforglipron)

Oral GLP-1 Receptor Agonist — small molecule · Oral tablet — once daily

12.4% mean body weight reduction at 72 weeks (ATTAIN-1) at the maximum dose alongside lifestyle changes.

ATTAIN-1 (2025); orforglipron Phase 3, Eli Lilly · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · ATTAIN-1 trial · MHRA licensed (2026) · SPS GLP-1 guidance · MHRA (GLP-1 RAs)

Reviewed by pharmacist: 13 November 2026

All cited evidence in Weight Loss Clinic (12)

  • SURMOUNT-1 (NEJM 2022)
  • NICE TA875 (2023)
  • STEP 1 (NEJM 2021)
  • OASIS-4 (NEJM 2025)
  • SELECT cardiovascular outcomes trial
  • first oral GLP-1 for weight loss
  • SCALE (NEJM 2015)
  • NICE TA661 (2022)
  • NICE CG189 (2014 updated 2023)
  • XENDOS trial
  • ATTAIN-1 (2025)
  • orforglipron Phase 3, Eli Lilly

Making healthy & happy easy to achieve

Platform metrics last updated13 Nov 2026 · 14:02

50,000+

Registered Patients

204,000+

Prescriptions Issued

1,000,000+

NHS Prescription Items Delivered

98%

Patient Satisfaction